PEGS Boston 2026: Design Is the Easy Part Now
Five days at PEGS Boston. The design question is mostly answered. The hard problems have moved to CMC tolerance and immune acceptance, and the field knows it.
Weekly field notes from inside antibody discovery and AI in pharma.
What the literature actually says, what the platforms get wrong, and what to build next.
Five days at PEGS Boston. The design question is mostly answered. The hard problems have moved to CMC tolerance and immune acceptance, and the field knows it.
Three signals this month, all pointing at the same thing: antibody discovery is becoming a computational discipline first and a wet-lab one second.
Antibody discovery is splitting into two cultures. One trusts the model. The other trusts the rabbit. Both had a good month.
Weekly. Three things from the literature, one take, no fluff.
Five days at PEGS Boston. The design question is mostly answered. The hard problems have moved to CMC tolerance and immune acceptance, and the field knows it.
Three signals this month, all pointing at the same thing: antibody discovery is becoming a computational discipline first and a wet-lab one second.
Antibody discovery is splitting into two cultures. One trusts the model. The other trusts the rabbit. Both had a good month.
Everyone frames nanobody humanization as CDR grafting. It's not. It's a search problem with a brutal fitness landscape.
A speaker-by-speaker recap of the European Life Science Informatics Forum Benelux #5 at GSK Wavre: data governance, FAIR, and agentic AI in drug discovery.
A quick tip showing how to untar or unzip multiple archive files in one go using find and tar.
Setting up Sublime Text 3 as a default IDE with Jekyll support and Markdown editing.
New posts on science, AI, bioinformatics and life. No spam, unsubscribe anytime.
Powered by Buttondown